CN1899523A - 一种治疗急、慢性咽喉炎的中药组合物及其制备方法 - Google Patents
一种治疗急、慢性咽喉炎的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN1899523A CN1899523A CN 200610091165 CN200610091165A CN1899523A CN 1899523 A CN1899523 A CN 1899523A CN 200610091165 CN200610091165 CN 200610091165 CN 200610091165 A CN200610091165 A CN 200610091165A CN 1899523 A CN1899523 A CN 1899523A
- Authority
- CN
- China
- Prior art keywords
- solution
- weight portion
- group
- adds
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000001154 acute effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 230000001684 chronic effect Effects 0.000 title claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 110
- 238000000034 method Methods 0.000 claims abstract description 61
- 230000008569 process Effects 0.000 claims abstract description 34
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000008187 granular material Substances 0.000 claims abstract description 18
- 239000007924 injection Substances 0.000 claims abstract description 9
- 238000002347 injection Methods 0.000 claims abstract description 9
- 238000001514 detection method Methods 0.000 claims abstract description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 5
- 235000011477 liquorice Nutrition 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 137
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 132
- 239000003826 tablet Substances 0.000 claims description 99
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 94
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 76
- 239000008194 pharmaceutical composition Substances 0.000 claims description 75
- 238000012360 testing method Methods 0.000 claims description 70
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 60
- 239000000706 filtrate Substances 0.000 claims description 50
- 239000003814 drug Substances 0.000 claims description 41
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 24
- 239000013558 reference substance Substances 0.000 claims description 24
- 239000011248 coating agent Substances 0.000 claims description 19
- 238000000576 coating method Methods 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 claims description 16
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 claims description 16
- 239000007941 film coated tablet Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 238000004809 thin layer chromatography Methods 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 14
- 239000007921 spray Substances 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 12
- 239000000853 adhesive Substances 0.000 claims description 12
- 230000001070 adhesive effect Effects 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 12
- 239000012567 medical material Substances 0.000 claims description 12
- 239000000741 silica gel Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 241000202807 Glycyrrhiza Species 0.000 claims description 6
- 241000736026 Sarcandra Species 0.000 claims description 6
- 241001530126 Scrophularia Species 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 claims description 4
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 claims description 4
- KIBLEPZGKRYXBB-UHFFFAOYSA-N butan-2-one ethyl acetate formic acid hydrate Chemical compound O.OC=O.CCC(C)=O.CCOC(C)=O KIBLEPZGKRYXBB-UHFFFAOYSA-N 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000003760 hair shine Effects 0.000 claims description 4
- 238000004811 liquid chromatography Methods 0.000 claims description 4
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 4
- 238000000079 presaturation Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 239000002893 slag Substances 0.000 claims description 4
- 238000011003 system suitability test Methods 0.000 claims description 4
- 239000012085 test solution Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract 1
- 240000004274 Sarcandra glabra Species 0.000 abstract 1
- 241000293861 Scrophularia nodosa Species 0.000 abstract 1
- 244000067645 Wedelia chinensis Species 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000009021 pien tze huang Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 74
- 241000699670 Mus sp. Species 0.000 description 38
- 229960004756 ethanol Drugs 0.000 description 33
- 208000011580 syndromic disease Diseases 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 201000007100 Pharyngitis Diseases 0.000 description 17
- 206010011224 Cough Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 239000013642 negative control Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 210000004400 mucous membrane Anatomy 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 206010036790 Productive cough Diseases 0.000 description 7
- 230000000954 anitussive effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 206010018691 Granuloma Diseases 0.000 description 6
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003172 expectorant agent Substances 0.000 description 6
- 230000003419 expectorant effect Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 6
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 241000581650 Ivesia Species 0.000 description 4
- 208000016150 acute pharyngitis Diseases 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 206010030094 Odynophagia Diseases 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000007330 chocolate agar Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical group O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical group [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 125000000017 cortisol group Chemical group 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012850 discrimination method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012372 quality testing Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001584 soft palate Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002396 uvula Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101000617395 Mus musculus Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003616 anti-epidemic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
序号 | 组别 | 动物数(只) | 剂量浓度(ml/只) | 鼠耳肿胀度(mg· X±SD) | 肿胀抑制率(%) | P值 |
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组无极膏软膏组 | 1010101010 | 水-0.0518.7%-0.0537.3%-0.0574.7%-0.050.05 | 17.8±1.312.2±3.811.0±4.910.3±5.011.4±3.7 | /33.738.142.036.0 | /<0.05<0.01<0.01<0.01 |
序号 | 组别 | 动物数(只) | 剂量(g·kg1) | 小鼠耳廓肿胀度(mg· X±SD) | 肿胀抑制率(%) | P值 |
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组氢化可的松组 | 1010101010 | 等量水10204025mg.ip | 18.7±4.215.0±3.113.1±4.210.9±4.59.5±3.2 | /19.831.941.749.2 | /<0.05<0.01<0.01<0.01 |
序号 | 组别 | 动物数(只) | 剂量(ml/只,3次/天) | 肉芽肿重量(mg/10gBW, X±SD) | 肿胀抑制率(%) | P值 |
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组康唑无极膏组 | 1010101010 | 等量水18.7%-0.0537.3%0.0574.7%0.0517%-0.05 | 10.2±2.58.9±2.96.1±1.85.7±1.32.7±1.3 | /12.339.943.873.4 | /<0.05<0.01<0.01<0.01 |
菌名 | 药物浓度(稀释倍数) | 无药对照组 | |||
1∶10 | 1∶15 | 1∶20 | 1∶40 | ||
乙型链球菌32209乙型链球菌(临床分离株)金黄色葡萄球菌26001粪链球菌32118大肠杆菌1299绿脓杆菌415肺炎杆菌(临床分离株)白色念珠菌 | ---++++- | ---+++++ | --++++++ | ++++++++ | ++++++++ |
序号 | 组别 | 动物数(只) | 剂量(ml/只,3次/天) | 酚红排出量(μg.ml-1 X±SD) | 相对百分率(%) | P值 |
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组氯化铵组 | 1010101010 | 等量水1020401 | 1.67±0.542.51±0.812.90±0.613.70±0.803.54±0.71 | 100150174222212 | <0.05<0.01<0.01<0.01 |
序号 | 组别 | 剂量(g·kg-1) | 动物数(只) | 排痰量(cm, X±SD) | ||
给药前 | 给药后 | 给药后/给药前(%) | ||||
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组氯化铵组 | 等水量1020401 | 88888 | 13.0±0.651.40±0.481.10±0.251.20±0.611.25±0.42 | 1.42±0.352.68±0.88***2.80±0.96***3.17±1.08***2.85±0.91*** | 109191254264228 |
序号 | 组别 | 剂量(g·kg-1) | 动物数(只) | 咳嗽潜伏期(S) | 咳嗽次数/2min |
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组磷酸可待因组 | 等量水10204030mg.ip | 1515151515 | 44±1644±1144±873±20**81±24*** | 33±1522±1020±9**12±10***8±6*** |
序号 | 组别 | 剂量(g/kb) | 动物数(只) | 咳嗽次数/5min |
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组磷酸可待因组 | 等量水1020405mg.ip | 1010101010 | 17±413±511±4**8±5***7±3*** |
序号 | 组别 | 剂量(g·kg-1) | 动物数(只) | 耳廓肿胀度(mg. X±SD) | 脾脂数(mg/10gBW. X±SD) | 胸脾指数(mg/10gBW. X±SD) |
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组氢化考的松组 | 等量水10101025mg.ip | 1010101010 | 15.8±1.816.0±4.412.5±4.5**13.0±3.0**10.8±4.6*** | 40±1045±1340±932±1224±13** | 30±1129±1029±722±87±22*** |
序号 | 组别 | 剂量(ml/只) | 动物数(只) | 痛阈值(S, X±SD) | |||
给药前 | 给药后自身对照的差值 | ||||||
15’ | 30’ | 60’ | |||||
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组无极膏软膏组 | 等量水18.7%-0.0537.3%-0.0574.7%-0.0515%-0.05 | 1010101010 | 15.3±4.115.0±3.615.6±3.015.3±3.916.6±3.4 | 0.3±4.03.3±1.7**5.3±3.4***5.8±2.3***9.0±6.4*** | 1.2±3.45.6±5.5**8.5±5.0***10.4±5.0***11.9±4.9*** | 0.8±5.23.4±3.03.4±2.38.6±4.6***9.1±5.1*** |
序号 | 组别 | 剂量(ml/只) | 动物数(只) | 电刺激反应阈值(V, X±SD) | ||
给药前 | 给药后 | 差值 | ||||
12345 | 阴性对照组药物组合物片剂药液组药物组合物片剂药液组药物组合物片剂药液组无极膏软膏组 | 等量水18.7%-0.0537.3%-0.0574.7%-0.0515%-0.05 | 1010101010 | 30±332±631±329±432±4 | 31±439±541±444±445±5 | 1±17±3***10±4***16±6***14±4*** |
组别 | 痊愈例数% | 显效例数% | 有效例数% | 无效例数% | 合计 | R | |||||
风热征虚火上炎症痰热证 | 治疗组对照组扩大组治疗组对照组扩大组治疗组对照组扩大组 | 23564000000 | 451037000000 | 221376207913719 | 432545712343593549 | 629237181081018 | 125714256047365046 | 046152132 | 084417105155 | 5151169283021222039 | 0.6528△0.34710.6172△0.37490.56490.42845 |
组别 | 总例数 | 治前 | 治后 | 前后差值 | |
风热证虚火上炎证痰热证 | 治疗组对照组扩大组治疗组对照组扩大组治疗组对照组扩大组 | 5151169283021222039 | 20.6224±5.856422.3496±6.741721.7253±6.809824.03±5.3023.37±5.5623.47±3.4727.72±4.4824.9±5.5927.07±5.27 | 3.3078±3.32587.6819±5.76244.2591±4.80386.32±5.0210.6±5.029.38±4.798.04±5.4911.15±5.579.53±5.07 | 17.0339±5.5764☆14.6657±6.6244☆17.4662±7.3982☆17.75±6.11☆△12.76±4.90☆14.09±5.57☆19.32±7.19☆13.75±4.73☆17.53±6.38☆ |
组别 | 痊愈例数% | 显效例数% | 有效例数% | 无效例数% | 合计 | R | |||||
急性 | 治疗组对照组扩大组 | 422595 | 8249356 | 81549 | 162929 | 11124 | 22214 | 001 | 001 | 5151169 | 0.5904△0.4096 |
组别 | 显效例数% | 有效例数% | 无效例数% | 合计 | R | ||||
急性 | 治疗组对照组扩大组 | 321956 | 643893 | 18293 | 36585 | 021 | 042 | 505060 | 0.5686△0.4314 |
组别 | 痊愈例数% | 显效例数% | 有效例数% | 无效例数% | 合计 | R | |||||
急性 | 治疗组对照组扩大组 | 4020125 | 803975 | 4415 | 889 | 62126 | 124115 | 062 | 0121 | 5051168 | 0.6148△0.3874 |
组别 | 显效例数% | 有效例数% | 无效例数% | 合计 | R | ||||
急性 | 治疗组对照组扩大组 | 291231 | 582452 | 213627 | 427245 | 022 | 043 | 505060 | 0.5892△0.4108 |
组别 | 痊愈例数% | 显效例数% | 有效例数% | 无效例数% | 合计 | R | |||||
急性慢性 | 治疗组对照组扩大组治疗组对照组扩大组 | 22576000 | 491256000 | 004281426 | 003562844 | 152029192828 | 335021385647 | 81528385 | 1838206168 | 45401375050590 | 0.5934△0.39270.5768△0.4232 |
组别 | 痊愈例数% | 显效例数% | 有效例数% | 无效例数% | 合计 | R | |||||
急性慢性 | 治疗组对照组扩大组治疗组对照组扩大组 | 221594000 | 814076000 | 01417333 | 033581070 | 514229146 | 193818324714 | 0743133 | 019310437 | 2737124293042 | 0.6263△0.40690.6455△0.3592 |
组别 | 痊愈例数% | 显效例数% | 有效例数% | 无效例数% | 合计 | R | |||||
急性 | 治疗组对照组扩大组 | 101286 | 835586 | 015 | 055 | 266 | 17276 | 033 | 133 | 1222100 | 0.59810.4465 |
组别 | 显效例数% | 有效例数% | 无效例数% | 合计 | R | ||||
急性 | 治疗组对照组扩大组 | 13535 | 522081 | 10172 | 40685 | 236 | 81214 | 252543 | 0.57840.4215 |
组别 | 显效例数% | 有效例数% | 无效例数% | 合计 | R | ||||
急性 | 治疗组对照组扩大组 | 1240 | 52160 | 9129 | 394875 | 293 | 93625 | 232512 | 0.6199△0.3894 |
组别 | 痊愈 | 显效 | 有效 | 无效 | 合计 | R | |||||
例数 | % | 例数 | % | 例数 | % | 例数 | % | ||||
急性慢性 | 治疗组对照组扩大组治疗组对照组扩大组 | 8939000 | 504158000 | 2021450 | 12.50358230 | 41114915 | 2550213868 | 221212 | 12.581849 | 1622672422 | 0.53620.47370.58640.4055 |
组别 | 痊愈 | 显效 | 有效 | 无效 | 合计 | R | |||||
例数 | % | 例数 | % | 例数 | % | 例数 | % | ||||
急性 | 治疗组对照组扩大组 | 272084 | 795574 | 115 | 334 | 61320 | 183618 | 024 | 064 | 3436113 | 0.56580.4379 |
组别 | 痊愈 | 显效 | 有效 | 无效 | 合计 | R | ||||
例数 | % | 例数 | % | 例数 | % | 例数 | % | |||
治疗组急性5天对照组扩大组治疗组急性7天对照组扩大组治疗组慢性14天对照组扩大组 | 1734929983000 | 33529571849000 | 23968181255331428 | 451840352433662849 | 10334542624153028 | 20652785014306049 | 167047264 | 21240844126 | 51511695151169505060 | 0.6515△0.34830.6468△0.35310.598△0.402 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610091165XA CN100475256C (zh) | 2006-07-04 | 2006-07-04 | 一种治疗急、慢性咽喉炎的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610091165XA CN100475256C (zh) | 2006-07-04 | 2006-07-04 | 一种治疗急、慢性咽喉炎的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1899523A true CN1899523A (zh) | 2007-01-24 |
CN100475256C CN100475256C (zh) | 2009-04-08 |
Family
ID=37655634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200610091165XA Active CN100475256C (zh) | 2006-07-04 | 2006-07-04 | 一种治疗急、慢性咽喉炎的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100475256C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102379910A (zh) * | 2010-09-03 | 2012-03-21 | 漳州片仔癀药业股份有限公司 | 片仔癀及其制剂在保护记忆功能和抗脑缺血方面的新用途 |
CN102698069A (zh) * | 2012-07-02 | 2012-10-03 | 张秀香 | 一种预防化疗所致口腔黏膜炎的口腔护理液 |
CN110082471A (zh) * | 2019-05-09 | 2019-08-02 | 四川逢春制药有限公司 | 一种桔梗冬花片的检测方法 |
CN110426486A (zh) * | 2019-08-01 | 2019-11-08 | 正大青春宝药业有限公司 | 中药制剂中浙麦冬的鉴别方法 |
-
2006
- 2006-07-04 CN CNB200610091165XA patent/CN100475256C/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102379910A (zh) * | 2010-09-03 | 2012-03-21 | 漳州片仔癀药业股份有限公司 | 片仔癀及其制剂在保护记忆功能和抗脑缺血方面的新用途 |
CN102379910B (zh) * | 2010-09-03 | 2013-04-10 | 漳州片仔癀药业股份有限公司 | 片仔癀及其制剂在保护记忆功能和抗脑缺血方面的新用途 |
CN102698069A (zh) * | 2012-07-02 | 2012-10-03 | 张秀香 | 一种预防化疗所致口腔黏膜炎的口腔护理液 |
CN110082471A (zh) * | 2019-05-09 | 2019-08-02 | 四川逢春制药有限公司 | 一种桔梗冬花片的检测方法 |
CN110082471B (zh) * | 2019-05-09 | 2021-04-27 | 四川逢春制药有限公司 | 一种桔梗冬花片的检测方法 |
CN110426486A (zh) * | 2019-08-01 | 2019-11-08 | 正大青春宝药业有限公司 | 中药制剂中浙麦冬的鉴别方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100475256C (zh) | 2009-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1740175A (zh) | 博落回总生物碱盐及其制备方法和应用 | |
CN1947754A (zh) | 一种治疗小儿哮喘的药物及其制备方法 | |
CN1872282A (zh) | 一种青天葵活性提取物及其制备方法和应用 | |
CN101040915A (zh) | 一种双黄连注射液的制备方法及其成分检测方法 | |
CN1899523A (zh) | 一种治疗急、慢性咽喉炎的中药组合物及其制备方法 | |
CN1723955A (zh) | 射干提取物及其制备方法和用途 | |
CN1857362A (zh) | 金感康药物制剂及其制备方法 | |
CN1248718C (zh) | 治疗支原体肺炎的药物组合物及其制备和质量控制方法 | |
CN1706480A (zh) | 复方甘草药物制剂及其制备方法 | |
CN1772026A (zh) | 一种返魂草提取物,它的提取方法及制剂 | |
CN1850202A (zh) | 一种***外用药物组合物及其制备方法和用途 | |
CN1606979A (zh) | 黄芩素作为解热、镇痛、抗炎、抗菌、抗病毒剂的作用 | |
CN1299734C (zh) | 一种治疗大肠湿热证的中药组合物及其制备方法 | |
CN101032571A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1304038C (zh) | 一种治疗***炎的药物组合物及其制备和质量控制方法 | |
CN1254266C (zh) | 感冒胶囊及其制备方法 | |
CN1698691A (zh) | 一种治疗肺热(毒)咳嗽的药物及其制备方法 | |
CN1824082A (zh) | 金地蓝解毒药物组合物、制剂及制备方法 | |
CN100335090C (zh) | 一种益肾蠲痹药物组合物及其制备方法 | |
CN1864707A (zh) | 杏香兔耳风***泡腾片及其制备方法 | |
CN1899560A (zh) | 一种用于治疗暑湿型感冒的复方制剂及其制备方法 | |
CN1589892A (zh) | 一种治疗急、慢性咽炎的药物组合物及其制备方法 | |
CN1732938A (zh) | 复方对乙酰氨基酚口腔崩解片 | |
CN1253170C (zh) | 一种治疗肝炎的中药制剂及其制备检测方法 | |
CN1919270A (zh) | 组合物,其提取物及它们的药物用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUARUN PIENTZEHUANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHONGZHOU PIANZIGUANG PHARMACEUTICAL INDUSTRY CO., LTD. Effective date: 20120815 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120815 Address after: 363000, Jing County, Nanjing County, Fujian, Zhangzhou Patentee after: China Resources Pien Tze Huang Pharmaceutical Co.,Ltd. Address before: 363000 Zhangzhou street, Fujian Patentee before: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20070124 Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. Assignor: China Resources Pien Tze Huang Pharmaceutical Co.,Ltd. Contract record no.: 2014990000154 Denomination of invention: Chinese medicine composition for treating acute and chronic largngopharyngitis and ts preparing method Granted publication date: 20090408 License type: Exclusive License Record date: 20140327 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. Assignor: China Resources Pien Tze Huang Pharmaceutical Co.,Ltd. Contract record no.: 2014990000154 Date of cancellation: 20171016 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20070124 Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. Assignor: China Resources Pien Tze Huang Pharmaceutical Co.,Ltd. Contract record no.: 2017990000409 Denomination of invention: Chinese medicine composition for treating acute and chronic largngopharyngitis and ts preparing method Granted publication date: 20090408 License type: Exclusive License Record date: 20171024 |
|
CP01 | Change in the name or title of a patent holder |
Address after: 363000, Jing County, Nanjing County, Fujian, Zhangzhou Patentee after: Fujian pianzehuang Health Technology Co.,Ltd. Address before: 363000, Jing County, Nanjing County, Fujian, Zhangzhou Patentee before: China Resources Pien Tze Huang Pharmaceutical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. Assignor: China Resources Pien Tze Huang Pharmaceutical Co.,Ltd. Contract record no.: 2017990000409 Date of cancellation: 20200904 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20070124 Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. Assignor: Fujian pianzehuang Health Technology Co.,Ltd. Contract record no.: X2020990000477 Denomination of invention: A traditional Chinese medicine composition for treating acute and chronic pharyngitis and its preparation method Granted publication date: 20090408 License type: Exclusive License Record date: 20200904 |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 18/F, Pianzihuang Building, No. 1 Amber Road, Xiangcheng District, Zhangzhou City, Fujian Province, 363000 Patentee after: Fujian pianzehuang Health Technology Co.,Ltd. Address before: 18/F, Pianzihuang Building, No. 1 Amber Road, Xiangcheng District, Zhangzhou City, Fujian Province, 363000 Patentee before: Fujian Pianzihuang Health Industry Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230315 Address after: 18/F, Pianzihuang Building, No. 1 Amber Road, Xiangcheng District, Zhangzhou City, Fujian Province, 363000 Patentee after: Fujian Pianzihuang Health Industry Co.,Ltd. Address before: 363000 Jingcheng New District, Nanjing County, Zhangzhou City, Fujian Province Patentee before: Fujian pianzehuang Health Technology Co.,Ltd. |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. Assignor: Fujian pianzehuang Health Technology Co.,Ltd. Contract record no.: X2020990000477 Date of cancellation: 20230928 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20070124 Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. Assignor: Fujian pianzehuang Health Technology Co.,Ltd. Contract record no.: X2023350000369 Denomination of invention: A traditional Chinese medicine composition for treating acute and chronic pharyngitis and its preparation method Granted publication date: 20090408 License type: Exclusive License Record date: 20231008 |
|
EE01 | Entry into force of recordation of patent licensing contract |